0.9899
4.42%
0.0419
プレマーケット:
.99
0.000100
+0.01%
前日終値:
$0.948
開ける:
$0.9689
24時間の取引高:
617.32K
Relative Volume:
1.75
時価総額:
$66.12M
収益:
-
当期純損益:
$-126.61M
株価収益率:
-0.5051
EPS:
-1.96
ネットキャッシュフロー:
$-60.14M
1週間 パフォーマンス:
+12.49%
1か月 パフォーマンス:
-16.82%
6か月 パフォーマンス:
-65.63%
1年 パフォーマンス:
-42.78%
Generation Bio Co Stock (GBIO) Company Profile
GBIO を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
GBIO
Generation Bio Co
|
0.9899 | 66.12M | 0 | -126.61M | -60.14M | -1.96 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Generation Bio Co Stock (GBIO) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-10-19 | ダウングレード | TD Cowen | Outperform → Market Perform |
2022-11-08 | 開始されました | Canaccord Genuity | Buy |
2021-12-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
2021-06-08 | 開始されました | JMP Securities | Mkt Outperform |
2021-02-24 | 開始されました | William Blair | Outperform |
2021-02-18 | 開始されました | Needham | Buy |
2020-07-07 | 開始されました | Cowen | Outperform |
2020-07-07 | 開始されました | JP Morgan | Overweight |
2020-07-07 | 開始されました | Jefferies | Buy |
2020-07-07 | 開始されました | Wedbush | Outperform |
すべてを表示
Generation Bio Co (GBIO) 最新ニュース
Generation Bio chief scientific officer Matthew Stanton to leave role - MSN
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Analysts Provide Insight Into Generation Bio Co’s (GBIO) Potential. - Stocks Register
Will Generation Bio (NASDAQ:GBIO) Spend Its Cash Wisely? - Yahoo Finance
Generation Bio Independent Director Acquires 131% More Stock - Yahoo Finance
Generation Bio Co. (NASDAQ:GBIO) Shares Sold by Jane Street Group LLC - Defense World
Generation Bio director Quinn Anthony buys $203k in shares By Investing.com - Investing.com South Africa
Generation Bio Co. (NASDAQ:GBIO) Director Anthony G. Quinn Purchases 125,791 Shares - MarketBeat
Anthony G. Quinn Purchases 85,000 Shares of Generation Bio Co. (NASDAQ:GBIO) Stock - MarketBeat
Generation Bio director Quinn Anthony buys $203k in shares - Investing.com
Seattle immunotherapy startup Umoja Biopharma raises $100M - GeekWire
Generation Bio (GBIO) Stock Price, News & Analysis - MarketBeat
Needham & Company LLC Issues Pessimistic Forecast for Generation Bio (NASDAQ:GBIO) Stock Price - Defense World
Generation Bio's SWOT analysis: ctLNP tech drives pivot to autoimmune stock - Investing.com Canada
Verdiva Bio, a New Clinical-Stage Cardiometabolic Company, Launches with Over $410M in Series A Financing to Advance Next-Generation Therapies - Business Wire
Finance Watch: Generation Bio, CytomX Right-Size Operations Ahead Of J.P. Morgan - News & Insights
Needham & Company LLC Lowers Generation Bio (NASDAQ:GBIO) Price Target to $8.00 - MarketBeat
Barclays PLC Boosts Position in Generation Bio Co. (NASDAQ:GBIO) - Defense World
Generation Bio Announces Executive Departures and Appointments - Defense World
Generation Bio Restructures Leadership and Focuses on siRNA - TipRanks
Generation Bio Co. Announces Executive Changes - Marketscreener.com
Generation Bio Co. to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases - Marketscreener.com
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune - EIN News
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases - The Manila Times
Generation Bio Pivots to Autoimmune Disease Treatment with Novel T Cell Technology - StockTitan
Generation Bio Co. (NASDAQ:GBIO) Holdings Raised by State Street Corp - Defense World
Generation Bio Co. (NASDAQ:GBIO) Short Interest Up 16.3% in December - MarketBeat
Contrasting Spyre Therapeutics (NASDAQ:SYRE) & Generation Bio (NASDAQ:GBIO) - Defense World
Next-Generation Biomanufacturing Market Vendor and Technology Assessment Report 2024-2031 - openPR
Generation Bio stock hits 52-week low at $1.11 By Investing.com - Investing.com South Africa
MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio - BioSpace
Generation Bio stock hits 52-week low at $1.11 - Investing.com
Generation Bio's SWOT analysis: innovative dna tech stock faces clinical hurdles By Investing.com - Investing.com South Africa
Generation Bio's SWOT analysis: innovative dna tech stock faces clinical hurdles - Investing.com Australia
BB Biotech AG Reduces Stake in Generation Bio Co: An In-Depth Analysis - GuruFocus.com
“Next-Generation Bioformulations” for Plant Growth Promotion and Stress Mitigation: A Promising Approach for Sustainable Agriculture | Request PDF - ResearchGate
Molecular Diagnostics Market to grow by USD 7.92 Billion (2024-2028), driven by rising age-related diseases; Report highlights AI-driven transformationTechnavio - Lelezard
US Penny Stocks Spotlight: LiveOne And 2 Other Promising Picks - Simply Wall St
Baker BROS. Advisors LP Acquires 737,988 Shares of Generation Bio Co. (NASDAQ:GBIO) - MarketBeat
Generation Bio Co. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Generation Bio Co. Reports Q3 2024 Financials and Progress - TipRanks
Generation Bio Co (GBIO) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):